Page 2 - Jay Mei News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Antengene Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to.

South koreaHong kongPeter qianJay meiAsia pacificAntengene corporation limitedCompany annualAntengene corporationMd anderson cancer centerAntengene shanghai officeHong kong stock exchangeFamily zhangChief medicalCancer centerCorporation limitedPatients beyond

Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to.

South australiaUnited statesBritish columbiaNew jerseyHong kongSouth koreaBo shanWestern australiaUnited kingdomCity ofJay meiShehara mendisGodfrey guoAnthonyj olszanskiPeter qianAdnan khattak

Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting

Antengene Presents Results from Five Investigational Programs at 2023 SITC Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaHong kongAsia pacificJay meiPeter qianAntengene corporationPrnewswire antengene corporation limitedMd anderson cancer centerDrug administrationCompany annualHong kong stock exchangeSociety of immunologyAntengene corporation limitedCorporation limitedCancer annual meetingInvestigational new drug

Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to.

United statesSouth koreaHong kongJay meiPeter qianAsia pacificHong kong stock exchangeAntengene corporationAntengene corporation limitedPrnewswire antengene corporation limitedCompany annualUniversity of texas md anderson cancer centerAmerican association for cancer research annual meetingCorporation limitedInstitutional review boardCancer center

Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline

/PRNewswire/ Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its interim results for the six-months ended June 30, 2023, and.

Hong kongUnited statesSouth koreaJay meiPeter qianAsia pacificHansoh pharmaHong kong stock exchangeAntengene corporation limitedScientific review committeeBank balance to provide runwayCompany annualNational reimbursement drug listMd anderson cancer centerAntengene corporationDrug administration